RU 43044

RU 43044 is an orally active, selective glucocorticoid receptor inhibitor. RU 43044 blocks glucocorticoid receptor activity and reverses the enhanced dopamine release induced by high potassium in the prefrontal cortex. RU 43044 also inhibits thymocyte receptor down-regulation induced by high-dose glucocorticoids without affecting thymocyte apoptosis or basal receptor expression. RU 43044 is widely applicable to research related to depression^[1][2][3]. In Vivo:RU 43044 (10-30 mg/kg; p.o.; administered at 23.5, 5, and 1 hours before experiments) produces antidepressant-like effects in chronic corticosterone-treated mice, reversing increased forced swim test immobility and enhanced prefrontal high K⁺-stimulated dopamine release, without altering motor function^[1].
RU 43044 (10-30 mg/kg; p.o.; administered at 23.5, 5, and 1 hours before experiments) produces antidepressant-like effects in isolation-reared mice, reversing increased forced swim test immobility and enhanced prefrontal high K⁺-stimulated dopamine release, without altering motor function^[1].
RU 43044 (1 mg/kg; i.p.; every 12 hours; 2 days) alone has no effect on normal thymocyte development or GCR expression, but it blocks high-dose Dexamethasone (HY-14648) -induced GCR down-regulation in mature single-positive thymocytes^[3].